We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 07 Apr 2025
Print article
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)

With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions. Now, a new collaboration aims to address one of the most pressing challenges in modern healthcare: timely and precise identification of infectious pathogens.

Biotia (New York, NY, USA) has entered into a joint development agreement with Mayo Clinic (Rochester, MN, USA) to propel precision medicine in infectious disease diagnostics. This collaboration seeks to combine Mayo Clinic's clinical expertise and diagnostics with Biotia's innovative microbial analytics platform to enhance patient care through faster, more accurate, and comprehensive infectious disease diagnostic solutions. Biotia's cutting-edge AI-powered sequence analysis capabilities will be used to identify and characterize pathogens isolated from clinical specimens, providing laboratories and clinicians with detailed strain level pathogen identities and actionable information.

Mayo Clinic will contribute its expertise in microbial diagnostics, clinical application, data interpretation, and patient care to ensure the solutions are optimized for real-world clinical use. Biotia's platform integrates next-generation sequencing with a curated pathogen database and advanced bioinformatics, delivering rapid and reliable results that empower clinicians to make informed treatment decisions. The collaboration is expected to yield new diagnostic solutions that will be piloted at Mayo Clinic, with the potential for broader deployment across healthcare systems worldwide.

"Together, we aim to reduce diagnostic uncertainty, enhance patient outcomes, and tackle global health challenges using precision diagnostics," said Dr. Niamh O'Hara, CEO and co-founder of Biotia.

Related Links:
Biotia
Mayo Clinic

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Sekisui Diagnostics UK Ltd.